Richmond Pharmacology is pleased to join the EASL Congress 2026 in Barcelona, Spain, on 27–30 May 2026.

As one of the world’s leading hepatology meetings, the EASL Congress brings together clinicians, researchers, industry experts, and global stakeholders to explore the latest advances in liver disease research, diagnostics, therapeutics, and clinical care.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer

Our Focus at the Congress

  • Emerging therapies and clinical strategies for liver disease
  • Translation of hepatology research into early‑phase clinical development
  • Biomarker‑driven approaches to trial design and patient selection
  • Evolving regulatory pathways for hepatology therapeutics
  • Collaboration across academia, industry, and global liver health communities

Connect With Us

If you are attending the EASL Congress 2026 and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: EASL Congress 2026 - EASL-The Home of Hepatology.

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event